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Response to the Letter by G. M. H. Swaen and R. Otter
This industry-funded commentary misrepresents the rigorous methodology used to evaluate human literature associ-
ating phthalate exposure with endometriosis. It ignores consistency in findings from human and animal studies and
substantial laboratory data strongly supporting causative effects carefully documented in our manuscript (1).
Given previous emphasis that Swaen has placed on documenting protocols for evaluating evidence (2), it is surprising
that Swaen and Otter omitted key details of their own approach. In contrast, our expert panel deliberations are openly
and transparently delineated (1). Indeed, studies included by Swaen andOtter suffer from crucial methodological flaws
(3–6), effectively biasing their meta-analysis results to the null. In contrast, we excluded as methodologically flawed
studies that relied on self-reported endometriosis rather than the “gold standard” of surgically visualized disease, that
used inappropriate comparison groups, or assessed phthalate exposure after diagnosis. Sample size was a secondary
consideration. In contrast, the Buck Louis et al (7) study usedmodern exposure assessment, age and residencematching
in recruitment, and direct surgical visualization of outcome in the operative cohort.
Although it has a short half-life, monoethylhexylphthalate (MEHP) is the most biologically active metabolite of
di-2-ethylhexylphthalate (DEHP) (8). However, Swaen and Otter do not acknowledge the statistical significance for
associations between endometriosis and four otherDEHPmetabolites in the population-based cohort of the Buck-Louis
et al (7) study. Furthermore, multiple sensitivity analyses confirmed robust statistical associations between DEHP
exposure and postoperatively confirmed diagnoses comparedwith women found to have a normal pelvis (7). Inter- and
intra-rater reliability in the diagnosis and staging of endometriosis was a particular strength of the operative cohort (9).
Although confirmation is needed, especially with longitudinal measurements of exposure, these findings in women
together with laboratory and animal studies provide solid evidence supporting a conclusion of likely causation. Un-
certainty was carefully considered in assessing probabilities of causation for this exposure-response relationship, fol-
lowing rigorous criteria established by the Intergovernmental Panel on Climate Change (10). Swaen and Otter do not
appear to recognize the substantial, 99%, probability that at least one endocrine-disrupting chemical (EDC) effect
across the 15 exposure-response relationships we studied is causal (11). Our median estimate of €163 billion in costs
represents a substantial underestimate of actual EDC-attributable disease, given its focus on  5% of EDCs, exami-
nation of a subset of health effects, and exclusion of human suffering and other societal costs of EDC-attributable
diseases (12).
The comments presented by Swaen and Otter do not diminish the impact of our conservatively formulated findings
for policymakers considering methods to reduce exposure to the EDCs of greatest concern. The economic rewards of
doing so are likely to be in the billions of Euros and accrue annually insofar as alternatives free of health effects are used.
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